急性白血病儿童接种BNT162b2疫苗的安全性与免疫原性
结果显示成人剂量30 μg耐受良好,无剂量限制性毒性;患儿体液应答低于同胞(52% vs 100%,p<0.001),但T细胞应答相似(80% vs 100%,p=0.1)。第三剂后43%患儿产生显著体液应答,且体液与T细胞应答持续至少一年,研究期间无重症COVID-19发生。
要点
- AL患儿接种30 μg BNT162b2耐受良好,未观察到剂量限制性毒性。
- 患儿体液应答低于同胞,但T细胞应答与同胞相似。
- 第三剂可使43%患儿产生显著体液应答,免疫应答持续至少一年。
核心结论
- 急性白血病儿童接种成人剂量(30 μg)BNT162b2耐受良好,即使化疗期间也能产生显著T细胞应答。
- 鉴于目前推荐儿童使用10 μg剂量,该结果支持在免疫抑制患者中增加疫苗剂量。
研究设计与样本
- PACIFIC试验(NCT04969601)为开放标签、两中心、1/2期剂量探索研究。
- 共同主要终点为安全性(剂量限制性毒性)和体液免疫原性(第二剂后一个月抗Spike IgG滴度≥260 BAU/ml)。
- 抗Spike IgG滴度<260 BAU/ml的儿童接受第三剂疫苗,免疫应答评估至首剂后12个月。
主要发现
- 剂量递增期间未观察到毒性,44/53名儿童接受30 μg疫苗剂量。
- 首剂后两个月,患儿体液应答低于同胞(52% vs 100%,p<0.001)。
- 患儿与同胞T细胞应答相似(80% vs 100%,p=0.1)。
- 第三剂后43%患儿产生显著体液应答。
- 体液和COVID-19特异性T细胞应答持续至少一年,研究期间无重症COVID-19发生。
临床怎么用
- 急性白血病患儿可考虑接种成人剂量(30 μg)BNT162b2以增强免疫应答。
- 对体液应答不足的患儿可考虑追加第三剂以提升体液免疫。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: COVID-19 can be severe in children with acute leukaemia (AL), significantly delaying chemotherapy. This is the first study to address the safety and immunogenicity of BNT162b2 in children with AL. METHODS: The PACIFIC trial (NCT04969601) was a phase 1/2 dose-finding study in children aged <15 years with AL and their siblings. Two doses of BNT162b2 vaccine were administered 21 days apart. The co-primary endpoints were safety, assessed by dose-limiting toxicity, and humoral immunogenicity, defined by an anti-Spike IgG titer ≥260 BAU/ml one month after the second injection. A third dose of vaccine was administered to children with an anti-Spike IgG titer <260 BAU/ml. Humoral and cellular immune responses were assessed for 12 months after the first vaccine injection. RESULTS: Sixty-one patients and 15 siblings were included. No toxicity was observed during dose escalation. Thus, 44/53 children received the 30 μg vaccine dose. Two months after the first injection, the humoral response was lower in patients than siblings (52 % vs 100 %, p < 0.001), whereas the T-cell response was similar in the two groups (80 % versus 100 %, p = 0.1). A significant humoral response was observed in 43 % of patients after the third dose. Both humoral and Covid-19-specific T-cell responses persisted for at least one year after vaccination. No severe Covid-19 occurred during the study. CONCLUSIONS: Vaccination of children with acute leukaemia with adult doses (30 μg) of BNT162b2 is well tolerated and results in significant T-cell response children with AL, even during chemotherapy. As doses of 10 μg is currently recommended for children, these results support the value of increasing vaccine doses in immunocompromised patients.
引用
- Alby-Laurent F, Ouedrani A, Jateau P, et al. Safety and immunogenicity of BNT162b2 vaccine in children with acute leukaemia: results and perspectives of an open-label, two-centre, phase 1/2 trial with dose finding study. Vaccine. 2026. PMID: 41507013. doi:10.1016/j.vaccine.2025.128130
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。